Skip to main content

Advertisement

Table 1 Baseline characteristics of the low excretor population, by treatment outcome(s): age, sex, race, height, weight, BMI and medication use.

From: Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety

    All First randomization Second randomization
     PRM Placebo PRM Placebo
   N 172 86 86 127 39
Characteristic Visit       
Age (years) 1 Mean (SD) 63.8 (9.3) 63.4 (9.8) 64.2 (8.8) 63.4 (9.6) 64.3 (8.3)
Sex   N (%) female 128 (74.4%) 63 (73.3%) 65 (75.6%) 96 (75.6%) 28 (71.8%)
Race*   N (%) white 170 (98.8%) 84 (97.7%) 86 (100.0%) 125 (98.4%) 39 (100.0%)
Height (m) 1 Mean (SD) 1.63 (0.08) 1.64 (0.09) 1.63 (0.08) 1.64 (0.09) 1.62 (0.08)
Weight (kg) 1 Mean (SD) 71.4 (13.1) 71.0 (14.0) 71.8 (12.2) 70.9 (13.4) 72.8 (12.3)
BMI (kg/m2) 1 Mean (SD) 26.7 (4.1) 26.4 (3.9) 27.1 (4.3) 26.4 (4.0) 27.7 (4.5)
Taking any medications 1 N (%) 17 (9.9%) 6 (7.0%) 11 (12.8%) 10 (7.9%) 6 (15.4%)
Taking codeine† 1 N (%) 29 (16.9%) 13 (15.1%) 16 (18.6%) 21 (16.5%) 8 (20.5%)
Taking codeine 2 N (%) 26 (15.1%) 16 (18.6%) 10 (11.6%) 21 (16.5%) 5 (12.8%)
Confirmed codeine analgesic 2 N (%) 15 (8.7%) 8 (9.3%) 7 (8.1%) 11 (8.7%) 4 (10.3%)
  1. *One patient missing observation.
  2. †Two patients missing observations at Visit 1.
  3. PRM, prolonged release melatonin; SD, standard deviation